Global Liquid Biopsy Market Report 2022: Increased Awareness Regarding Cancer Boosts 13.77% Annual Growth

DUBLIN, Nov. 8, 2022 /PRNewswire/ -- The "Global Liquid Biopsy Market By Offering, By Technology, Next Generation Sequencing, By Workflow, By Sample, By Circulating Biomarkers, By Application, By End User, By Region Competition Forecast & Opportunities, 2027" report has been added to  ResearchAndMarkets.com's offering.

The global liquid biopsy market was valued at USD 2,728.57 million in 2021, and during the forecast period, it is expected to expand at a CAGR of 13.77%. An alternate way of detecting and diagnosing cancer is liquid biopsy. The primary reason propelling the growth of the liquid biopsy market is the rising incidence of cancer worldwide. Liquid biopsies aid in the early detection of cancer while traditional biopsy techniques do not allow the detection of cancer in the aged population.

Due to factors such as the rising prevalence of cancer, increased funding for research to find new biomarkers, and increased emphasis on the use of liquid biopsy, the market is anticipated to experience rapid expansion.

The rise of the industry is partly a result of substantial investments made by biotechnology firms in the research and development of liquid biopsies. A further factor driving the growth of the liquid biopsy market in the years to come is the increasing use of liquid biopsy among prominent end users.

Rising Incidence of Cancer

Several factors, including tobacco use, alcohol use, poor food, physical inactivity, and air pollution, are contributing to the rise in cancer cases in the modern world. The global incidence of cancer is rising, making it the second biggest cause of death. Breast cancer is now the most prevalent type of cancer diagnosed worldwide due to the increased prevalence of the disease among females.

Growing Adoption of Liquid Biopsy among Major End Users

As prospective screening, diagnostic, prognostic, and predictive tests in cancer, liquid biopsies have gained a lot of interest. Clinical oncology has undergone a significant revolution owing to liquid biopsy, which makes it easier to sample tumors, provide continuous monitoring through repeated sampling, enable the creation of specific treatment plans, and test for therapeutic resistance. Since most cancers are in contact with blood, liquid biopsy mostly includes blood collection, though mucosa, pleural effusions, urine, and cerebrospinal fluid (CSF) are also examined during the procedure. As a result, Liquid Biopsy offers improved diagnosis sensitivity and simplicity of recurring sampling throughout therapy in a far more practical and non-invasive manner.

Increased Awareness Regarding Cancer

Today's population is more aware of the signs and symptoms of cancer, and they try to have their illness diagnosed when it is still in its early stages. As a result of early cancer detection, tumor progression monitoring, and clinical prognosis assessment capabilities, liquid biopsy technology is experiencing market expansion.

Report Scope:

In this report, Global Liquid Biopsy Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Liquid Biopsy Market, By Offering:

• Testing Service
• Kits
• Platform
• Other consumables

Liquid Biopsy Market, By Technology:

• Polymerase Chain Reaction
• Next Generation Sequencing
• Others

Liquid Biopsy Market, By Workflow:

• Sample Preparation
• Library Preparation
• Sequencing
• Data Analysis & Management

Liquid Biopsy Market, By Sample:

• Blood
• Urine
• Saliva
• Others

Liquid Biopsy Market, By Circulating Biomarkers:

• Circulating Tumor Cells (CTCs)
• Cell-free Nucleic Acids
• Exosomes & Extracellular Vesicles
• Others

Liquid Biopsy Market, By Application:

• Oncological
• Non- Oncological

Liquid Biopsy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Netherlands
• Belgium
• Denmark
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia
• New Zealand
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• Turkey
• Egypt
• Saudi Arabia
• South Africa
• UAE

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Liquid Biopsy Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Patent Analysis

8. Global Liquid Biopsy Market Outlook

9. North America Liquid Biopsy Market Outlook

10. Europe Liquid Biopsy Market Outlook

11. Asia-Pacific Liquid Biopsy Market Outlook

12. South America Liquid Biopsy Market Outlook

13. Middle East and Africa Liquid Biopsy Market Outlook

14. Market Dynamics

15. Market Trends & Developments

16. Competitive Landscape (Inclusive of SWOT Analysis)

17. Strategic Recommendations

18. About the Publisher & Disclaimer

Companies Mentioned

• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific, Inc.
• PerkinElmer Inc.
• LungLife AI, Inc.
• Illumina, Inc.
• QIAGEN NV
• NeoGenomics Laboratories, Inc.
• Myriad Genetics, Inc.
• Biocept, Inc.
• Bio-Rad Laboratories, Inc.
• Guardant Health Inc.
• Natera, Inc.
• Sysmex Corporation
• Abcodia Ltd.
• Dxcover Limited

For more information about this report visit https://www.researchandmarkets.com/r/s2ibuv

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets